Tesamorelin (5mg Vial) Dosage Protocol
A stabilized GHRH analog that stimulates natural growth-hormone release and reduces visceral fat - FDA-approved (Egrifta) for HIV-associated lipodystrophy; other uses are research/educational only.
Stabilized GHRH (1-44) analog; stimulates pituitary GH release, raising IGF-1 and reducing visceral abdominal fat.
2 mg (2000 mcg) once daily subcutaneously, the FDA-approved regimen, after an optional 1 mg first-week titration.
2.5 mL bacteriostatic water per 5 mg vial gives 2.0 mg/mL for accurate insulin-syringe dosing.
Refrigerate the lyophilized vial (Egrifta SV is room-temp stable); refrigerate the reconstituted solution and do not freeze it.
Mix & measure Tesamorelin · 5 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard FDA-Approved Protocol (2.5 mL = 2.0 mg/mL)
Reconstitute: Add 2.5 mL bacteriostatic water to one 5 mg vial → final concentration 2.0 mg/mL (2,000 mcg/mL).
Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously — the FDA-approved regimen — with an optional 1 mg first week for tolerability.
Easy measuring: At 2.0 mg/mL, 1 unit ≈ 20 mcg on a U-100 syringe, so the 2 mg dose reads at a clear 100 units.
Storage: Refrigerate the lyophilized vial at 2–8 °C (35.6–46.4 °F) (Egrifta SV is stable at room temperature); after reconstitution, refrigerate at 2–8 °C and do not freeze the mixed solution.